Northwire Canada EditionFriday, July 10, 2026
Northwire
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
M&A / Property Routine +

Fluent enters definitive deal to sell Cansortium Texas

Fluent Divests Texas Unit for $30M to Deleverage Ahead of Vireo Merger

Executive Summary
  • Event: Fluent Corp. entered a definitive agreement to sell its Texas business operations (Cansortium Texas LLC) to Legacy Therapeutics LLC.
  • Consideration: Total purchase price of $30 million ($25 million at closing, $2.5 million on first anniversary, $2.5 million on second anniversary).
  • Assets Included: Cultivation, manufacturing, delivery in Schulenburg, TX, and retail operations in Houston.
  • Use of Proceeds: Primarily to repay a portion of existing senior secured debt; remainder for working capital.
  • Context: This announcement follows the April 30, 2026 announcement that Vireo Growth Inc. will acquire Fluent Corp. in an all-stock transaction.
Material Impact
  • Positive Cash Flow Impact: The immediate $25 million cash inflow is material given the company reported only ~$8.9 million in cash as of December 31, 2025, and a "going concern" doubt in its audited statements. This significantly improves short-term liquidity.
  • Strategic Contradiction: The sale contradicts the December 31, 2025 announcement which stated management would sharpen focus on core growth markets including Texas ("Florida, New York, Texas"). Selling Texas suggests a pivot driven by liquidity needs or specific terms of the Vireo acquisition rather than organic strategic preference.
  • Debt Reduction: With $72.2 million in total debt outstanding (Dec 31), this sale reduces leverage materially but does not eliminate it entirely. The deferred payments ($5 million) provide less immediate relief than the upfront cash.
  • Alignment with M&A: This divestiture aligns with the April 30 Vireo deal narrative which mentioned "streamlining operations through asset divestitures." It appears to be a cleanup step prior to the merger closing in Q4 2026.
FNT · Price
Company Overview
  • Overview: Fluent Corp. is a multi-state operator (MSO) focused on medical cannabis markets, primarily Florida, New York, Texas, and Pennsylvania (recently divested).
  • Flagship Project: The Rosa indoor cultivation facility in Florida (Tampa campus), which completed first harvests in November 2025, adding ~25% capacity.
  • Brand Portfolio: KNACK (premium flower/pre-rolls), Connected, Alien Labs (New York distribution).
  • Operational Status: Undergoing significant restructuring and divestitures to support a merger with Vireo Growth Inc.
Read the original news release →

More from Fluent Corp